We have further built on these findings by demonstrating the role of GPR182 scavenging of CXCL9 and CXCL10 by LECs in the TME of murine melanoma, implicating lymphatic GPR182 as a potential therapeutic target in cancer immunotherapy. The gene discussed is CXCL9; the disease is melanoma.